- Price
- $146.23
- Day
- -3.69%
- Mkt Cap
- $14.70B
- 52W Range
- $122.14 – $186.12
- Volume
- 2.82M
- Beta
- 0.38
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Corient Private Wealth LP increased its position in shares of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) by 21.4% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 54,680 shares of the company's stock after purchasing an additional 9,645 shares during
Read full article
Integrated Wealth Concepts LLC lowered its position in Neurocrine Biosciences, Inc. (NASDAQ: NBIX) by 41.5% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 8,041 shares of the company's stock after selling 5,703 shares during the period. Integrated Wealth Concepts
Read full article
Neurocrine Biosciences, Inc. (NBIX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Read full article
Engineers Gate Manager LP raised its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) by 64.0% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 18,361 shares of the company's stock after purchasing an additional 7,163 shares during the period.
Read full article
Amundi lifted its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) by 8.3% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 220,463 shares of the company's stock after purchasing an additional 16,826 shares during the quarter. Amundi owned 0.22% of
Read full article
Neurocrine Biosciences, Inc. (NBIX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Read full article
Neurocrine Biosciences, Inc. (NBIX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Read full article
Continuum Advisory LLC decreased its position in shares of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) by 99.1% during the undefined quarter, according to its most recent disclosure with the SEC. The firm owned 418 shares of the company's stock after selling 43,650 shares during the period. Continuum Advisory LLC's holdings in Neurocrine Biosciences were
Read full article
SAN DIEGO, Sept. 2, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its executives will participate at the following investor conferences: Wells Fargo 21 st Annual Healthcare Conference.
Read full article
NBIX's Crenessity gains rapid traction in CAH, with sales soaring and low patient penetration leaving room for growth.
Read full article